Author

Jasmeet Anand

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5035299131

P915: Treatment Patterns and Clinical Outcomes of Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-cd38 Monoclonal Antibody: Findings From the Connect Mm Disease Registry

2023 · Rafat Abonour, Robert Rifkin, et al. · HemaSphere

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

2022 · Hans C. Lee, Rafat Abonour, et al. · Blood

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

2022 · Joshua Richter, Sikander Ailawadhi, et al. · Blood

Works count: 3

Citation count:

H-index:

I10-index: